The Rate Of Disease Progression In MS Patients Treated With Rituximab And Ocrelizumab: A Comparative Study

Suzan A. Hamza; Namir I. A. Haddad; Gheyath AL Gawwam

doi:10.29284/x4mwhb26

Authors

Suzan A. Hamza Department of Chemistry, College of Science, University of Baghdad, Baghdad, Iraq.
Namir I. A. Haddad Department of Chemistry, College of Science, University of Baghdad, Baghdad, Iraq.
Gheyath AL Gawwam Department of Neurology, College of Medicine, University of Baghdad, Baghdad, Iraq.

DOI:

https://doi.org/10.29284/x4mwhb26

Keywords:

Multiple sclerosis, Rituximab, Ocrelizmub, EDSS, CD20+, progression index.

Abstract

New disease-modifying treatments (DMTs), like monoclonal antibodies (mAbs), have improved clinical outcomes and led to major shifts in MS treatment guidelines. Since these mAbs like rituximab and ocrelizumab have varying degrees of efficacy; our study aimed to evaluate and compare rituximab and ocrelizumab by terms of their potency in lowering disability scores, slowing disease progression and clinical relapse, and depleting B cells in Iraqi patient with MS. Fifty-eight Iraqi patient with MS were enrolled, and divided equally based on the medication used into two groups; 29 patients medicated with Rituximab and 29 patients medicated with Ocrelizumab. Each of EDSS, PI and clinical relapse were calculated, moreover serum Albumin was measured using Biosystem kit, while CRP measured by using immunoturbidimetric assay. B- cell depletion was measured by using flowcytometry technique. EDSS mean (before and after treatment) among patients treated with RTX didn’t show any difference (EDSS1=3.19 vs. EDSS2=3.2), while the patients treated with OCR showed a notable deterioration in EDSS even after treatments (EDSS1= 3.93 vs. EDSS2= 5.1). Moreover, there was a significant decrease in clinical relapses among RTX treated-patients (27.6%) compared to OCR treated-patients (17.17). The percent of PI in RTX group showed significant decrement than that of OCR group (44% vs. 56%), also, a high significant depletion in B cell was noticed in RTX group compared to OCR group (0.48 vs. 0.70). In contrast to OCR, which revealed a substantial worsening of EDSS following treatment, RTX demonstrated no statistically significant difference in EDSS (pre- and post-treatment). Also, patients treated with RTX had much lower rates of PI, relapses, and higher B cell depletion as compared to patients treated with OCR. So, these findings indicate that rituximab exceeds ocrelizumab in slowing the course of illness.

References

1. Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., ... & Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology, 17(2), 162-173.

2. Sahib, S. A., Sulaiman, G. M., Waheed, H. J., & Albukhaty, S. (2024). Evaluate the Levels of Serum Eotaxin-1, Myelin Basic Protein, and Some Immunological and Biochemical Markers in Iraqi Patients with Multiple Sclerosis. Iraqi Journal of Science, 126-137.

3. McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021). Diagnosis and treatment of multiple sclerosis: a review. Jama, 325(8), 765-779.

4. Sabatino, J. J., Zamvil, S. S., & Hauser, S. L. (2019). B-cell therapies in multiple sclerosis. Cold Spring Harbor Perspectives in Medicine, 9(2), a032037.

5. Pavlasova, G., & Mraz, M. (2020). The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy. Haematologica, 105(6), 1494.

6. Delgado, S. R., Faissner, S., Linker, R. A., & Rammohan, K. (2024). Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. Journal of neurology, 271(4), 1515-1535..

7. Trouvin, A. P., Jacquot, S., Grigioni, S., Curis, E., Dedreux, I., Roucheux, A., ... & Goëb, V. (2015). Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study. Clinical & Experimental Immunology, 180(1), 11-18.

8. Merrill, J. T., Neuwelt, C. M., Wallace, D. J., Shanahan, J. C., Latinis, K. M., Oates, J. C., ... & Brunetta, P. G. (2010). Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: the randomized, double‐blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 62(1), 222-233.

9. Mageau, A., Bonnotte, B., Ebbo, M., Dossier, A., Galicier, L., Souchaud-Debouverie, O., ... & Godeau, B. (2023). Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study. Platelets, 34(1), 2200848.

10. Fahad, Q. A. (2021). Paediatric multiple sclerosis: a case report of missed and dismissed diagnosis. Journal of the Faculty of Medicine Baghdad, 63(1), 36-39.

11. Dalla Costa, G., Leocani, L., & Comi, G. (2022). Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis. Expert Review of Clinical Immunology, 18(2), 105-114.

12. Brancati, S., Gozzo, L., Longo, L., Vitale, D. C., & Drago, F. (2021). Rituximab in multiple sclerosis: are we ready for regulatory approval?. Frontiers in Immunology, 12, 661882.

13. Costa, G. D., & Comi, G. (2023). A safety review of current monoclonal antibodies used to treat multiple sclerosis. Expert Opinion on Drug Safety, 22(11), 1011-1024.

14. Dalla Costa, G., Leocani, L., & Comi, G. (2022). Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis. Expert Review of Clinical Immunology, 18(2), 105-114.

15. Carlson, A. K., Amin, M., & Cohen, J. A. (2024). Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability. Drugs, 84(3), 285-304.

16. Boyko, O. V., Boyko, A. N., Yakovlev, P. A., Zinkina-Orikhan, A. V., Kotov, S. V., Linkova, Y. N., ... & Ivanov, R. A. (2019). Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): pharmacokinetics, pharmacodynamics and safety. Zhurnal nevrologii i psikhiatrii imeni SS Korsakova, 119(10. Vyp. 2), 87-95.

17. McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021). Diagnosis and treatment of multiple sclerosis: a review. Jama, 325(8), 765-779..

18. Bar-Or, A., O’Brien, S. M., Sweeney, M. L., Fox, E. J., & Cohen, J. A. (2021). Clinical perspectives on the molecular and pharmacological attributes of anti-CD20 therapies for multiple sclerosis. CNS drugs, 35(9), 985-997.

19. Sarsour, K., Beckley‐Kartey, S., Melega, S., Odueyungbo, A., Kirchner, P., Khalife, N., & Bangs, J. (2020). Rituximab utilization for approved and off‐label nononcology indications and patients’ experiences with the Patient Alert Card. Pharmacology Research & Perspectives, 8(1), e00555.

20. Rae-Grant, A., Day, G. S., Marrie, R. A., Rabinstein, A., Cree, B. A., Gronseth, G. S., ... & Pringsheim, T. (2018). Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology, 90(17), 777-788.

21. Klein, C., Lammens, A., Schäfer, W., Georges, G., Schwaiger, M., Mössner, E., ... & Niederfellner, G. (2013, January). Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. In MAbs (Vol. 5, No. 1, pp. 22-33). Taylor & Francis.

22. Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H. P., Hemmer, B., ... & Kappos, L. (2017). Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine, 376(3), 221-234.

23. Hauser, S. L., & Cree, B. A. (2020). Treatment of multiple sclerosis: a review. The American journal of medicine, 133(12), 1380-1390.

24. Alharbi, M. A., Aldosari, F., Althobaiti, A. H., Abdullah, F. M., Aljarallah, S., Alkhawajah, N. M., ... & AlRuthia, Y. (2023). Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia. BMC Health Services Research, 23(1), 552.

25. Roos, I., Hughes, S., McDonnell, G., Malpas, C. B., Sharmin, S., Boz, C., ... & MSBase Study GroupDanish MS Registry Study Group. (2023). Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis. JAMA neurology, 80(8), 789-797.

26. Granqvist, M., Boremalm, M., Poorghobad, A., Svenningsson, A., Salzer, J., Frisell, T., & Piehl, F. (2018). Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA neurology, 75(3), 320-327.

27. Alping, P., Frisell, T., Novakova, L., Islam‐Jakobsson, P., Salzer, J., Björck, A., ... & Piehl, F. (2016). Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of neurology, 79(6), 950-958.

28. Hellgren, J., Strandberg, M. C., Källén, K., & Svenningsson, A. (2024). A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab. Multiple Sclerosis Journal–Experimental, Translational and Clinical, 10(2), 20552173241252566.

29. Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., ... & Wolinsky, J. S. (2017). Ocrelizumab versus placebo in primary progressive multiple sclerosis. New england journal of medicine, 376(3), 209-220.

30. Mazdeh, M., Khamseh, M., Taheri, M., & Ghafouri-Fard, S. (2020). Effect of rituximab on Expanded Disability Status Scale and relapse rate in multiple sclerosis patients. Journal of Molecular Neuroscience, 70, 1165-1168.

31. Mohammadia, H. R., Erfania, A., Jamshidbeigib, Y., Rahmatianc, A., & Otaghid, M. (2024). Effect of using rituximab on disability in patients with multiple sclerosis. Risk, 5(7).

32. Ongphichetmetha, T., Jitprapaikulsan, J., Siritho, S., Rattanathamsakul, N., Detweeratham, T., & Prayoonwiwat, N. (2024). Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder. Scientific Reports, 14(1), 3503.

33. Houtchens, M., & Howard, D. (2024). Ocrelizumab in highly disabled progressive multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 82, 105345.

34. Alshawaf, F., Ahmed, S., Al-Hashel, J., & Alroughani, R. (2023). Ocrelizumab and Cladribine had similar EDSS stability and safety profile in patients with highly active multiple sclerosis (P8-3.011). Neurology, 100(17_supplement_2), 3255.

35. de Sèze, J., Maillart, E., Gueguen, A., Laplaud, D. A., Michel, L., Thouvenot, E., ... & Liblau, R. (2023). Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. Frontiers in Immunology, 14, 1004795.

36. Tian, X., Chen, C., Ma, L., Wei, R., Li, M., Wang, X., ... & Cui, Y. (2020). Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis. Journal of neuroimmunology, 347, 577317.

37. Naegelin, Y., Naegelin, P., von Felten, S., Lorscheider, J., Sonder, J., Uitdehaag, B. M., ... & Derfuss, T. (2019). Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA neurology, 76(3), 274-281.

38. Granqvist, M., Boremalm, M., Poorghobad, A., Svenningsson, A., Salzer, J., Frisell, T., & Piehl, F. (2018). Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA neurology, 75(3), 320-327.

39. Naegelin, Y., Naegelin, P., von Felten, S., Lorscheider, J., Sonder, J., Uitdehaag, B. M., ... & Derfuss, T. (2019). Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA neurology, 76(3), 274-281.

40. Kletzl, H., Gibiansky, E., Petry, C., Mercier, F., Guenther, A., Wang, Q., ... & Hauser, S. (2019). Pharmacokinetics, pharmacodynamics and exposure-response analyses of ocrelizumab in patients with multiple sclerosis (N4. 001). Neurology, 92(15_supplement), N4-001.

41. Lafi, Z. K., & Mohammed, B. J. (2024). Association between vitamin D receptor (APAI rs7975232) genotypes and vitamin D serum levels in Iraqi multiple sclerosis patients. Translational Science of Rare Diseases, 7(1-2), 39-46.

42. Hussein, H. B., Ali, A. M., Abdulhassan, R. A., & Mohsin, Z. H. (2024). Investigation of Multiple Sclerosis in Iraqi Patients: Evaluation of Circulating IL 17α. Annals of RSCB, 28(1), 322-327.

43. Eren, F., & Demir, A. (2020). C-reactive protein/albumin ratio in patients with multiple sclerosis and its relationship with disease subtype and disability. Journal of Surgery and Medicine, 4(11), 974-977.